FDA green and red lights: April 2024
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
Make or break time for Iovance
Lifileucel heads up the list of upcoming US FDA catalysts.
A tumour-agnostic label for Enhertu leads April’s US oncology approvals.
Lifileucel heads up the list of upcoming US FDA catalysts.
